A hallmark of chronic hepatitis B virus (CHB) infection is the presence of high circulating levels of non-infectious small lipid HBV surface antigen (HBsAg) vesicles. Although rare, sustained HBsAg loss is the idealized endpoint of any CHB therapy. A novel small molecule RG7834 has been previously reported to inhibit HBsAg expression by targeting terminal nucleotidyltransferase protein 4A and 4B (TENT4A and TENT4B ). In this study, we describe a genome-wide CRISPR screen to identify other potential novel host factors required for HBsAg expression and to gain further insights into the mechanism of RG7834. We report more than 60 genes involved in regulating HBsAg and identified novel factors involved in RG7834 activity, including a zinc finger CCHC-type containing 14 (ZCCHC14) protein. We show that ZCCHC14, together with TENT4A/B, stabilizes HBsAg expression through HBV RNA tailing, providing a potential new therapeutic target to achieve functional cure in CHB patients.
GRAPHICAL ABSTRACT SUMMARY
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INTRODUCTION
Chronic hepatitis B virus (CHB) infection is a global public health concern affecting approximately 257 million people leading to risk of severe liver disease, including cirrhosis and hepatocellular carcinoma (Trepo et al., 2014) . CHB is attributed to the maintenance of an intrahepatic pool of the viral covalently closed circular DNA (cccDNA), which serves as the transcriptional template for all viral gene products required for replication (Nassal, 2015) . The most widely used antiviral therapies, nucleos(t)ide analogs, are effective at preventing infectious virus production and spread, but have no impact on cccDNA or the expression of HBsAg and other viral gene products. During CHB, HBsAg is expressed in large excess and circulates within small, non-infectious lipid vesicles which have been suggested to interfere with the host immune responses ((Lebosse et al., 2017) and reviewed in (Bertoletti and Ferrari, 2012; Faure-Dupuy et al., 2017) ). Although rarely seen in response to existing drugs, loss of circulating HBsAg is clinically correlated with viral clearance. Along with seroconversion, sustained HBsAg reduction is considered an important clinical endpoint for HBV therapies and a key parameter associated with functional cure (Zoulim and Durantel, 2015) .
To investigate mechanisms of reducing HBsAg, we performed a genome-wide CRISPR screen resulting in the identification of several novel host factors required for HBsAg expression. Using this approach, we also interrogated the mechanism of a small molecule inhibitor of HBsAg expression (RG7834), which was recently shown to destabilize HBV transcripts through interactions with the non-canonical poly(A) RNA polymerases TENT4B (PAPD5) and TENT4A (PAPD7) (Han et al., 2018; Mueller et al., 2019; Mueller et al., 2018) . Here we provide strong evidence that a newly implicated host factor, ZCCHC14, together with TENT4B and TENT4A, stabilizes HBsAg expression through HBV RNA tailing (nontemplated addition to the 3' terminus of the RNA). This mechanism is dependent on the HBV post-transcriptional regulatory element (PRE) and
is disrupted by RG7834. These results not only further expand our understanding of how HBsAg expression is regulated, but also provide an avenue for potential new therapeutic targets for drug development.
RESULTS

A genome-wide CRISPR screen to identify host factors required for HBV transcription
To identify host factors required for HBsAg expression, we established a FACSbased genome-wide CRISPR screen in a HepG2 cell line containing an integrated 1.1mer HBV genome (HepG2-HBV) ( Figure 1A) . Genome editing by CRISPR was enabled through the transduction of HepG2-HBV cells with lentivirus expressing Cas9 and a clonal cell line was selected that maintained stable high-level Cas9 expression over several passages (Cas9 HepG2-HBV, Figure S1A ). The efficiency of genome editing was evaluated using a FLAER assay that measures disruption of the cellular enzyme phosphatidylinositol glycan complementation class A (PIG-A) in glycosylphosphatidylinositol (GPI)-anchor protein biosynthesis pathway (Brodsky, 2009; Estoppey et al., 2017) . Using this method, Cas9 editing efficiency at 21 days was determined to be >90% ( Figure S1B ) and results were confirmed by next-generation sequencing (NGS) across the PIG-A gene locus ( Figure S1C ). Editing efficiency of the HBsAg gene in the integrated HBV genome was also evaluated by FACS analysis of intracellular HBsAg and an AlphaLISA assay of extracellular HBsAg at 14 and 21 days post-transduction. Intracellular HBsAg levels were reduced by 83-91% and extracellular HBsAg levels were reduced by 47-90%, depending on the sgRNA (Figures S1D and S1E). High efficiency editing of the integrated HBV genome was confirmed by NGS analysis ( Figure S1F ).
To perform the genome-wide CRISPR screen, Cas9 HepG2-HBV cells were transduced with a pooled puromycin-selectable lentiviral sgRNA library targeting 19,050 human protein-coding genes with five sgRNAs per target gene (DeJesus et al., 2016) .
The general workflow is shown in Figure 1A . Briefly, Cas9 HepG2-HBV cells were transduced with lentivirus at low multiplicity of infection (MOI = 0.5) in two independent replicates, followed by puromycin selection for 24 days to allow efficient CRISPR gene editing. Cells were then stained using an HBsAg antibody and sorted by FACS into
HBsAg-high and HBsAg-low populations ( Figure S2A ). Genomic DNA was then isolated and analyzed by NGS to determine the abundance of each sgRNA-encoding sequence within the sorted populations.
With the exception of one sample (RE-04-UV84, unsorted replicate 2), which was removed from downstream analysis, all samples had a minimum of 1x10 7 NGS reads ( Figure S2B ); approximately 90% of which aligned to expected barcodes from the pooled libraries ( Figure S2C ). Genes were then assigned a score based on the log2-transformed fold-change of sgRNA counts in unsorted samples compared to the sgRNA counts in the input CRISPR library. sgRNAs targeting essential cellular factors, including the ribosomal subunits (RPS8, RPS3A, and RPS13), were found in lower abundance than in the input CRISPR library ( Figure S2D ), while sgRNAs against the tumor suppressor gene TP53
were highly enriched ( Figure S2E ). Observation of the expected behavior of these sgRNAs validated the pooled CRISPR genome-wide screening approach.
Novel host factors involved in HBsAg production identified in genome-wide
CRISPR screen
To identify host factors involved in HBsAg expression, enrichment of sgRNAtargeted genes was compared between populations expressing high and low levels of HBsAg. Using a 2-fold cutoff, this analysis identified 22 genes that appeared to promote HBsAg expression ("pro-HBsAg") and 38 genes that reduced HBsAg levels ("anti-HBsAg") ( Figure 1B and 1C). Gene ontology analysis revealed significant enrichment of peroxisomal pathway(s) factors among genes that promoted HBsAg expression (redundant siRNA activity (RSA) = 17.8, with enrichment in 14 genes), while anti-HBsAg genes included those from the ER-associated protein degradation (ERAD) pathway (RSA = 4.72, with enrichment in 5 genes) ( Figures S3A and S3B , Table S1 ). The most enriched pro-HBsAg gene was zinc finger CCHC-type containing 14 (ZCCHC14). ZCCHC14 is a 949 amino acid protein containing one putative zinc-binding motif of the form Cys-X2-Cys-X4-His-X4-Cys, referred to as a 'Zn-knuckle' (Fields et al., 2008) .
To validate the impact of selected host factors on HBV replication, siRNA mediated knockdown of individual genes was performed ( Figure 1D ). HepG2-HBV cells were transfected with siRNA SMARTpools targeting each individual gene and HBsAg levels were determined by FACS (intracellular) and HBsAg AlphaLISA (extracellular) assays at 5 days post-transfection. Gene knockdown was confirmed by qRT-PCR ( Figure S4A ).
Consistent with the screening results, knockdown of pro-HBsAg genes ZCCHC14, NXT1, or ENY2 reduced both intracellular and extracellular HBsAg levels, with knockdown of ZCCHC14 leading to the most pronounced decrease in HBsAg production ( Figure 1E and Figure S4B ). Knockdown of the anti-HBsAg genes DCAF7, UBE2J1, RNF139, or UBE2J2
boosted intracellular HBsAg levels relative to NTC siRNA ( Figure S4B ). Extracellular
HBsAg levels, however, were not changed ( Figure 1E ) suggesting that the cellular machinery has reached maximum secretion of HBsAg (Huovila et al., 1992) . Together, these results validate selected genes as host factors that either promote or restrict HBsAg expression.
ZCCHC14, TENT4B, and PARP10 are involved in RG7834 activity
To further explore the factors that regulate HBsAg expression, we investigated a small molecule inhibitor of HBV replication, RG7834 (EC50 = 0.4nM, Figure S4C ) and expanded the genome-wide CRISPR screen to include compound-treated cells. Cas9
HepG2-HBV cells were transduced with the pooled puromycin-selectable lentiviral sgRNA library, followed by puromycin selection for 14 days. Transduced cells were then divided into three groups and treated with RG7834 (30pM or 30nM) or DMSO for 10 days.
A low dose (30pM; ~IC20) of RG7834 was used to identify factors (when knocked out) could potentiate the activity of the compound; a higher dose of RG7834 (30nM; ~IC80) was used to identify factors required for RG7834 activity.
Knockout of poly(ADP)-ribose polymerase family member 10 (PARP10), a protein known to promote tumorigenesis by alleviating replication stress (Schleicher et al., 2018) possibly potentiates RG7834 activity (Figure 2A ). This finding was validated by treating HepG2-HBV cells with OUL35, a selective small-molecule inhibitor of PARP10 (Venkannagari et al., 2016) . When cells were treated with OUL35 (1µM) alone for 5 days, no effect was detected in extracellular HBsAg levels. However, when cells were treated with both OUL35 (1µM) and RG7834 (1nM), extracellular HBsAg levels were significantly lower compared to RG7834 treatment alone ( Figure 2B ) without causing cellular toxicity (data not shown). Analysis of host genes essential for activity of RG7834 identified TENT4B, WT1
interacting protein (WTIP), and ZCCHC14 ( Figure 2C and 2D). WTIP showed the lowest fold-change among these genes and was not examined further. TENT4B has been previously identified as a target of RG7834 from a yeast-three-hybrid approach, but had not been validated biochemically (Mueller et al., 2019) . We therefore established an assay to measure the polymerase/polyadenylation activity of purified TENT4B. In this assay, polyadenylation of a template RNA (polyA15) was monitored indirectly by measuring ATP depletion over time using Kinase-glo (Promega). To rule out non-specific ATP hydrolysis, we also measured AMP/ADP production by ADP-glo (Promega). Purified TENT4B demonstrated robust RNA-dependent ATP depletion, without detectable levels of free AMP/ADP ( Figure S4D ). Addition of RG7834 was found to inhibit TENT4B polymerase activity with an IC50 = 1.3nM, whereas an RG7834 enantiomer (RO0321) was ~60-fold less potent ( Figure 2E and 2F). These findings suggest that RG7834 is an inhibitor of TENT4B polymerase/polyadenylation enzymatic activity.
ZCCHC14 works in conjunction with the TENT4A/B to tail HBV RNAs
In vivo, TENT4B functions as part of the larger TRAMP-like complex (Hamill et al., 2010; Houseley and Tollervey, 2009 ). The complex consists of three subunits highly conserved across eukaryotic organisms: a non-canonical poly(A) polymerase (TENT4B or TENT4A in mammals; Trf4/5 in yeast), a Zn-knuckle protein (ZCCHC7 in mammals;
Air1/2 in yeast), and an RNA helicase (MTR4) (Fasken et al., 2011; Hamill et al., 2010) .
Very little has been reported regarding ZCCHC14, except that it is also a Zn-knuckle protein.
To evaluate the roles of ZCCHC14 and multiple members of the TRAMP-like complex in HBV replication and gene expression, HepG2-HBV cells were transfected with siRNAs for 5 days and gene knockdown confirmed by qRT-PCR ( Figure S4A ).
Knockdown of TENT4B, TENT4A, or ZCCHC7 alone had minimal effect on intracellular or extracellular HBsAg protein levels. Simultaneous knockdown of TENT4A/B was required for a moderate reduction in intracellular HBsAg and a pronounced reduction in extracellular HBsAg ( Figures 3A and 3B ). In contrast, knockdown of ZCCHC14 alone strongly suppressed HBsAg to levels comparable to RG7834 treated cells with minimal alone (data not shown). ZCCHC14 does not appear to control TENT4B expression, since depletion of ZCCHC14 did not alter TENT4B protein levels ( Figure S4E ). We reconfirmed these findings and the role of ZCCHC14 and the TRAMP-like members in HBsAg expression using HBV de novo infected HepG2-NTCP1 cells ( Figures S4F and S4G ). We note that siRNA-mediated knockdown of ZCCHC14 (as well as TENT4A/B) also reduced intracellular levels of HBV DNA ( Figure 3C ) -an effect that would not be expected from modulation of HBsAg mRNA levels alone. This suggests that the effect on RNA accumulation may extend to pre-genomic RNA as well.
One of the key factors involved in mRNA stability regulation by the TRAMP complex is the length of the polyA tail (Vanacova et al., 2005) . Consistent with previous reports (Mueller et al., 2019) , we saw a decrease in RNA abundance and moderate increases in electrophoretic mobility of all HBV transcripts (including pre-genomic RNA) isolated from cells treated with RG7834, TENT4B siRNA, or TENT4A/B siRNAs; knockdown of either TENT4A or ZCCHC7 had no observable impact on HBV RNA mobility ( Figure 3E ). To evaluate the tail lengths of HBV transcripts, we performed an RNA tail length assay ( Figure 3F ) and using HBV-specific forward and reverse primers positioned upstream of the RNA tailing site verified target-specific amplification. In this assay, RG7834 treatment and ZCCHC14 knockdown had the most profound effect on HBV RNA tails length, with ZCCHC14 knockdown closely phenocopying RG7834 inhibitor treatment. TENT4B and TENT4A/B knockdown also reduced HBV RNA tails length, but to a lesser extent ( Figure 3G ). Actin RNA tails were unchanged, indicating that the effect was not due to a global reduction in RNA tailing.
Intact stem loop alpha (SLα) of HBV PRE is critical for ZCCHC14 activity
The activity of RG7834 has previously been shown to depend on a stem loop structure within the 5' end of the PRE, termed SLα. Deletions and mutations of SLα abrogated the inhibitory activity of RG7834, although the mechanism of this effect is still unclear . To determine whether this RNA element works in concert with the putative unconventional TRAMP-like complex, we generated a non-infectious HBV reporter cell line (HBV Rluc) in which the entire HBsAg coding region was replaced with a Renilla luciferase (Rluc) reporter downstream of the preS1/S2 promoters, while retaining the entire PRE and authentic HBV 3'UTR ( Figure 4A ). Given these findings, we next sought to further characterize this potential complex between ZCCHC14 and TENT4B. Co-immunoprecipitation using a TENT4B antibody in HepG2-HBV cells was able to pull-down ZCCHC14 ( Figure 4D ). We were unable however, to confirm this interaction using a ZCCHC14 antibody to pulldown TENT4B.
This could be due to low levels of endogenous TENT4B isoforms. To further investigate the binding of RG7834, we used a cellular protein thermal shift assay to determine the effect of RG7834 binding on the thermal stability of TENT4B and ZCCHC14 in cellular lysates. In this assay, compound binding is predicted to increase the thermal stability of 
DISCUSSION
One of the strongest confirmed pro-HBsAg factors identified from the genome-wide CRISPR screen was ZCCHC14. Interestingly, ZCCHC14 also came up as an efficacy target of RG7834, along with a previously identified target of the compound, TENT4B (Mueller et al., 2019) . Our results suggest a novel complex consisting of ZCCHC14 and TENT4A/B, which functions to stabilize HBV mRNA by promoting 3'-end tailing and thereby likely preventing degradation of the tail by exonucleases ( Figure 4J ). This complex resembles the TRAMP-like machinery, but with ZCCHC14 replacing ZCCHC7.
For cellular mRNAs, polyadenylation by the TRAMP-like complex was originally shown to target RNAs for degradation by the nuclear exosome (Boele et al., 2014; LaCava et al., 2005) . Recently, however, TENT4A/B were shown to protect mRNAs from degradation by adding mixed poly(A) tails with intermittent non-adenosine residues (Lim et al., 2018) .
It was also noted that transcripts encoding secreted proteins are frequently guanylated and are affected strongly by TENT4A/B depletion. Our results suggest a protective activity for the modified TRAMP-like complex on HBsAg mRNA, although it remains to be shown if this involves non-adenosine addition.
HBV RNA tailing is unique due to the circular, overlapping nature of the cccDNA genome. The polyadenylation signal (UAUAAA) on the terminally redundant genomic transcript (3.5-kb) is known to function poorly, in fact it is recognized only upon the second encounter with the polyadenylation machinery (Simonsen and Levinson, 1983) . HBV employs a number of RNA elements to boost polyadenylation and translation (Russnak and Ganem, 1990; Simonsen and Levinson, 1983) , including a 3'-PRE that enhances viral gene expression and mRNA nuclear export (Huang and Liang, 1993; Huang and Yen, 1994 RNA tailing activity and results in HBV RNA destabilization ( Figure 4J ).
In addition to identifying genes essential for RG7834 activity, we identified PARP10
as a host factor that negatively impacts RG7834 activities, including HBV integration into host DNA (Dandri et al., 2002; Gao et al., 2002; Kuny and Sullivan, 2016) .
Using a genome-wide CRISPR screen, we identified 60 genes that appeared to promote or reduce HBsAg levels. Unexpectedly, we identified several ubiquitination proteins with anti-HBsAg activity. Disruption of UBE2J1, RNF139, UBE2J2 and DCAF7 resulted in increased HBsAg levels, suggesting HBsAg could be a natural substrate for therapeutic modulation by targeted protein degradation approach (Lai and Crews, 2017) .
Also of interest was the peroxisomal pathway. It was striking that 14 peroxisomeassociated genes were enriched in the pro-HBsAg set. Some of these encode structural components of the peroxisome, while others encode genes that affect targeting of proteins to this organelle. We do not know the basis for the strong association of peroxisome-associated genes with HBsAg biogenesis but it has previously been shown that HBsAg biosynthesis involves budding of nascent chains into a pre-Golgi compartment (Huovila et al., 1992; Simon et al., 1988) . Peroxisomes are also known to derive from the ER; our results could indicate that the compartment in which HBsAg forms may share components with the peroxisome or a precursor thereof. Also, the role of peroxisomes in lipid metabolism, including the beta-oxidation of fatty acids and the biosynthesis of phospholipids maybe important for HBsAg assembly into lipoprotein particles (Lodhi and Semenkovich, 2014; Satoh et al., 1990) . Several studies have shown that peroxisome proliferator-activated receptor alpha agonists increase transcription and replication of HBV (Guidotti et al., 1999; Tang and McLachlan, 2001) .
In conclusion, a genome-wide CRISPR screen provided a powerful strategy for identifying new genes and pathways that control HBsAg expression. In addition, we demonstrate this unbiased approach as a tool for dissecting the potential mechanism of inhibitors of HBsAg expression. In particular, we provide the first evidence for a role of ZCCHC14 in augmenting the stability of HBsAg mRNA through HBV RNA tailing by TENT4A/B as part of an unconventional TRAMP-like complex. These results suggest a potential new therapeutic target for interrupting HBV replication and gene expression in CHB.
STAR METHODS
Mammalian cell culture, cell line generation and small molecule
HepG2 cells (obtained from ATCC) were cultured in DMEM/F12, GlutaMAX (Life Technologies), 10% fetal bovine serum (FBS, Gibco), and 100 U/mL penicillin/streptomycin (Gibco) at 37°C and 5% CO2. HepG2-hNTCP and HepG2-HBV were generated and cultured as previously described (Tropberger et al., 2015) . The Cas9
HepG2-HBV cell line was generated through lentiviral delivery of Cas9 
Pooled genome-wide CRISPR screening
The human genome-wide sgRNA library targeting 19,050 protein-coding genes was designed, constructed, and packaged as described in detail (Potting et al., 2018) .
The screen was performed in duplicate by transduction of the sgRNA libraries split between two pools (Cpool1 and Cpool3) at an MOI determined by a 12-point doseresponse ranging from 0 to 400 μL of viral supernatants in the presence of 5 μg/mL polybrene. Infection rate was determined by FACS as a percentage of red fluorescent protein (RFP)-positive cells and selection was optimized by determining the puromycin dose required to achieve >95% cell killing in 5 days.
For the genome-wide screen, cells were seeded at 1x10 Illumina library construction, sequencing, and genome-wide CRISPR screen data analysis were performed as previously described (Potting et al., 2018 For genome-wide CRISPR screen data analysis, raw sequencing reads were aligned to the appropriate library through Bowtie analysis with no mismatches (Langmead et al., 2009) . Differential fold-change estimates between samples were generated for each sgRNA using DESeq2 (Love et al., 2014) and effects on proliferation were assessed by comparison of the unsorted cell population to the input library. For gene-based hit calling, consistency of all sgRNAs per gene were considered (Konig et al., 2007) and plotted against the second strongest sgRNA as a representative. For gene-set enrichment analyses, the gene-set database was compiled from multiple sources including Reactome, NCBI Biosystems, and Gene Ontology, and the hits were calculated using a hypergeometric overrepresentation test. Benjamini-Hochberg-corrected p-values were calculated for each gene set and combination of input gene list size.
Validation of genes by siRNA knockdown
To evaluate activity of individual genes against HBV in HepG2-HBV, HepG2-hNTCP, and HBV reporter cell lines, cells were plated either in a 6-well or 96-well format in antibiotic-free medium. The following day transfection mixtures were prepared by diluting siRNAs (Dharmacon) and DharmaFECT1 transfection reagent (Dharmacon) in
Opti-MEM (Gibco) following manufacturer's instructions. For the HBV siRNA control, we used the siRNA sequence previously described and validated (Morrissey et al., 2005) .
The ON-TARGET plus human siRNA SMARTpools were purchased from Dharmacon: ZCCHC14 (23174; L-014086-01), NXT1 (29107; L-017194-00), ENY2 (56943; L-018808-01), DCAF7 (10238; L-019999-00), UBE2J2 (118424; L-008614-00), RNF139 (11236; L-006942-00), UBE2J1 (51465; L-007266-00), ZCCHC7 (84186; L-014804-01), TENT4B (64282; L-010011-00), TENT4A (11044; L-009807-00). For the non-target control, the ON-TARGET plus non-targeting pool (D-001810-10) was used. Transfection complexes were formed at room temperature and added to the plated cells for 24 hours. RG7834 or DMSO was also added to the cells at day 1 post-plating. For de novo infection, HepG2-hNTCP cells were infected with cell culture-derived HBV two days post plating as previously described (Tropberger et al., 2015) . Infected cells were incubated for an additional 7 days and HBsAg levels assessed by immunofluorescence. In HepG2-HBV cells, supernatants and cells were harvested and used for HBV marker analysis at 5-6 days post-transfection. In HBV reporter cells lines, luminescence was measured with
Renilla-Glo Luciferase assay following manufacturer's instructions at 3 days posttransfection. Cell viability was determined by Cell Titer Glo (Promega). All siRNA knockdowns were validated by qRT-PCR analysis of the targeted mRNAs. All experiments were performed with at least two biological replicates and several technical repeats.
HBsAg measurements
For intracellular HBsAg analysis by FACS, cells were harvested by trypsinization and 1x10 5 -3x10 5 cells/well were fixed with BD Cytofix/Cytoperm fixation/permeabilization solution (BD Biosciences) for 15 min at 4°C. Cells were washed twice with 1X BD Perm/Wash buffer (BD Biosciences) and stained with primary human HBsAg antibody (CR8097; US9512201 at 1.5 µg/ml) for 1h at 4°C. After two washes with BD Perm/Wash buffer, cells were stained with APC-conjugated mouse anti-human IgG antibody (Southern Biotech; 1:500) for ~45 min at 4°C. Following incubation, samples were washed with BD Perm/Wash buffer, resuspended in PBS and analyzed by BD FACSCanto II flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (Treestar, Inc.).
HBsAg in culture medium was detected with an AlphaLISA developed in house.
Five days post drug or siRNA treatment, supernatant from the culture plate was transferred to 384-well tissue-culture treated white opaque plate (Greiner Bio-one) and mixed with 50mM Tris assay buffer containing AlphaLisa acceptor and donor custom conjugated beads with in house generated human anti-HBsAg antibodies. Four hours after incubation at room temperature, the release of singlet oxygen was excited at 680nM and the emission of light signal was detected at 615nM using the Envision Plate Reader (Perkin Elmer).
For HBsAg analysis by immunofluorescence, cells were fixed with 4% (wt/vol) paraformaldehyde in PBS at room temperature for 15min. After washing with PBS, cells were incubated with blocking buffer [3% (wt/vol) BSA, 0.5% Triton X-100, 10% (vol/vol) FBS in 1× PBS] for 30-60 min followed by an hour incubation at room temperature with the HBsAg antibody (CR8097) diluted to 1.5 µg/mL in incubation buffer [3% (wt/vol) BSA, 0.5% Triton X-100 in 1× PBS]. The cells were washed twice with PBS and stained in the dark at room temperature for 30 min with NucBlue Fixed Cell ReadyProbes reagent -DAPI (ThermoFisher) and the secondary APC-conjugated mouse anti-human IgG antibody (Southern Biotech) diluted 1:1,000 in incubation buffer. After two washes in PBS, images were acquired with ImageXpress® and analyzed with MetaXpress®. For each condition, infections were done in triplicate with nine images acquired per replicate.
Total intracellular HBV DNA analysis by qPCR
For total intracellular HBV DNA quantification, normalized total DNA extracted with DNeasy Blood & Tissue Kit (Qiagen) following manufacturer's instructions was quantified by qPCR with primers described in (Zhu et al., 2011) using QuantiFast Probe PCR Master Mix (Qiagen). qPCR was run on ABI7900HT (Applied Biosystems) with PCR cycling conditions as follows: 95°C for 3min; and 95°C for 3s, 60°C for 30s for 40 cycles.
RNA extraction and cDNA synthesis
RNA was extracted with TRIZOL (ThermoFisher) following manufacturer's instructions. For cDNA synthesis, 500ng of total RNA was reverse transcribed using SuperScript VILO Master Mix at 42°C for 1 h with reverse transcriptase heat inactivated at 85°C for 5 min. The resulting cDNA was diluted 1:10 in water, and 1µL was used for qPCR analysis using FAST SYBR green master mix (Applied Biosystems) with 1X
PrimeTime IDT primers. Each primer pair reaction was run in triplicate following on ABI7900HT (Applied Biosystems) with PCR cycling conditions as follows: 95°C for 20s;
and 95°C for 3s, 60°C for 30s for 40 cycles.
Northern blotting
To detect HBV transcripts, Northern blotting was executed as described in (Tropberger et al., 2015) . Briefly, one microgram of RNA samples and 2µL of Millennium RNA ladder (ThermoFisher) were run on a denaturing 1% (wt/vol) agarose gel electrophoresis with reagents from the Northern Max Kit (Ambion) and transferred to Nytran membrane (TurboBlot kit) by using the TurboBlotter system (GE Healthcare).
Ribosomal RNAs was visualized with methylene blue solution (Sigma-Aldrich). A DIGlabeled (-) strand HBV RNA probe was transcribed from ScaI-linearized pGEM3Z-HBV plasmid with DIG Northern Starter Kit (Roche) according to manufacturer's instructions.
Hybridization at 68°C, washes, and detection with CDP-star (Roche) were carried out according to manufacturer's instructions. Images were acquired with the Azure c600
Imaging System (Azure Biosystems).
RNA tail-length assay
RNA tail length was analyzed using the Poly ( 
TENT4B ATP depletion assay
The TENT4B ATP depletion activity was performed in assay buffer (25mM Tris-HCL pH 7.5, 50mM KCl, 5mM MgCl2, 325mM EDTA, 0.02% Tween-20, 5% glycerol, 1mM
DTT, 0.01% BSA, 2% DMSO) containing 15nM purified TENT4B, 125nM in poly(A15) and 1µM ATP. ATP depletion was readout at multiple time-points using Kinase Glo kit following manufacturer's instructions (Promega).
Co-immunoprecipitation
HepG2-HBV cells were washed with PBS and lysed in Pierce™ IP lysis buffer 
Cellular thermal shift assay
HepG2-HBV cells were treated with 10µM RG7834 or DMSO for 1h at 37°C in PBS containing protease inhibitor before being heated for 3 min at various temperatures. Cells were snap frozen in liquid nitrogen and lysed by repeated freeze thaw cycle. Cell lysates were cleared by centrifugation to remove precipitated and aggregated proteins. Protein expression levels were determined by western blotting and quantified by densitometry.
Western blotting
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